ID

18137

Description

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00056160

Link

https://clinicaltrials.gov/show/NCT00056160

Keywords

Versions (1)
  1. 10/22/16 10/22/16 -
Uploaded on

October 22, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT00056160

English

Eligibility Multiple Myeloma NCT00056160

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
prior or current diagnosis durie-salmon stage ii or iii multiple myeloma.
Description

Multiple Myeloma | Staging

Data type

boolean

Alias
UMLS CUI [1]
C0026764
UMLS CUI [2]
C0332305
no more than 3 previous anti-myeloma regimens
Description

Regimen Quantity Against Multiple Myeloma

Data type

boolean

Alias
UMLS CUI [1,1]
C0040808
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0521124
UMLS CUI [1,4]
C0026764
no high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.
Description

Dexamethasone High dose

Data type

boolean

Alias
UMLS CUI [1,1]
C0011777
UMLS CUI [1,2]
C0444956
measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
Description

Multiple Myeloma Serum paraprotein level result | Multiple Myeloma Urine paraprotein level result | Specimen Collection 24 Hours

Data type

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C1318383
UMLS CUI [2,1]
C0026764
UMLS CUI [2,2]
C1318384
UMLS CUI [3,1]
C0200345
UMLS CUI [3,2]
C1442770
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior development of disease progression during high-dose dexamethasone containing therapy.
Description

Dexamethasone High dose | Disease Progression

Data type

boolean

Alias
UMLS CUI [1,1]
C0011777
UMLS CUI [1,2]
C0444956
UMLS CUI [2]
C0242656
laboratory abnormalities: absolute neutrophil count less than 1,000 cells/mm cubed
Description

LABORATORY ABNORMALITIES | Absolute neutrophil count

Data type

boolean

Alias
UMLS CUI [1]
C1853129
UMLS CUI [2]
C0948762
laboratory abnormalities: platelet count less than 75,000/mm cubed
Description

LABORATORY ABNORMALITIES | Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C1853129
UMLS CUI [2]
C0032181
laboratory abnormalities: serum creatinine greater than 2.5 mg/dl
Description

LABORATORY ABNORMALITIES | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C1853129
UMLS CUI [2]
C0201976
laboratory abnormalities: serum glutamic oxaloacetic transaminase (sgot, aspartate transaminase [ast]) or serum glutamic pyruvic transaminase (sgpt, alanine transaminase [alt])greater than 3.0 x upper limit of normal
Description

LABORATORY ABNORMALITIES | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C1853129
UMLS CUI [2]
C0201899
UMLS CUI [3]
C0201836
laboratory abnormalities: serum total bilirubin greater than 2.0 mg/dl
Description

LABORATORY ABNORMALITIES | Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1853129
UMLS CUI [2]
C1278039
prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.
Description

Malignant Neoplasms | Multiple Myeloma

Data type

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0026764
known hypersensitivity to thalidomide or dexamethasone.
Description

Hypersensitivity Thalidomide | Dexamethasone allergy

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0039736
UMLS CUI [2]
C0571611
development of a desquamating rash while taking thalidomide.
Description

Thalidomide | Rash desquamating

Data type

boolean

Alias
UMLS CUI [1]
C0039736
UMLS CUI [2]
C0542171
Back to the top of the page

Similar models

Eligibility Multiple Myeloma NCT00056160

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma | Staging
Item
prior or current diagnosis durie-salmon stage ii or iii multiple myeloma.
boolean
C0026764 (UMLS CUI [1])
C0332305 (UMLS CUI [2])
Regimen Quantity Against Multiple Myeloma
Item
no more than 3 previous anti-myeloma regimens
boolean
C0040808 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0521124 (UMLS CUI [1,3])
C0026764 (UMLS CUI [1,4])
Dexamethasone High dose
Item
no high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.
boolean
C0011777 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
Multiple Myeloma Serum paraprotein level result | Multiple Myeloma Urine paraprotein level result | Specimen Collection 24 Hours
Item
measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
boolean
C0026764 (UMLS CUI [1,1])
C1318383 (UMLS CUI [1,2])
C0026764 (UMLS CUI [2,1])
C1318384 (UMLS CUI [2,2])
C0200345 (UMLS CUI [3,1])
C1442770 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Dexamethasone High dose | Disease Progression
Item
prior development of disease progression during high-dose dexamethasone containing therapy.
boolean
C0011777 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Absolute neutrophil count
Item
laboratory abnormalities: absolute neutrophil count less than 1,000 cells/mm cubed
boolean
C1853129 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Platelet Count measurement
Item
laboratory abnormalities: platelet count less than 75,000/mm cubed
boolean
C1853129 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Creatinine measurement, serum
Item
laboratory abnormalities: serum creatinine greater than 2.5 mg/dl
boolean
C1853129 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
LABORATORY ABNORMALITIES | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
laboratory abnormalities: serum glutamic oxaloacetic transaminase (sgot, aspartate transaminase [ast]) or serum glutamic pyruvic transaminase (sgpt, alanine transaminase [alt])greater than 3.0 x upper limit of normal
boolean
C1853129 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
LABORATORY ABNORMALITIES | Serum total bilirubin measurement
Item
laboratory abnormalities: serum total bilirubin greater than 2.0 mg/dl
boolean
C1853129 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Malignant Neoplasms | Multiple Myeloma
Item
prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.
boolean
C0006826 (UMLS CUI [1])
C0026764 (UMLS CUI [2])
Hypersensitivity Thalidomide | Dexamethasone allergy
Item
known hypersensitivity to thalidomide or dexamethasone.
boolean
C0020517 (UMLS CUI [1,1])
C0039736 (UMLS CUI [1,2])
C0571611 (UMLS CUI [2])
Thalidomide | Rash desquamating
Item
development of a desquamating rash while taking thalidomide.
boolean
C0039736 (UMLS CUI [1])
C0542171 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial